HbA1c as a Marker of Diabetic Dyslipidemia in Type 2 Diabetic Patients: A Cross Sectional Study.

Devarmani SS, VG Warad, Mohammed Ayaz.

dc.contributor.author	Devarmani SS, VG Warad, Mohammed Ayaz.
dc.date.accessioned	2019-11-23T12:48:50Z
dc.date.available	2019-11-23T12:48:50Z
dc.date.issued	2015
dc.identifier.uri	http://hdl.handle.net/123456789/1332
dc.description.abstract	Cardiovascular morbidity & mortality are predominantly seen in diabetic patients with dyslipidemia. But unfortunately, most of the diabetic patients are unaware of their dyslipidemic status. By diagnosing & initiating steps to normalize the levels of circulating lipids, the odds of developing cardiovascular complications and mortality can be decreased. Long term glycemic control can be monitored using glycosylated hemoglobin (HbA1c	en_US
dc.language.iso	en	en_US
dc.publisher	BLDE(Deemed to be University)	en_US
dc.subject	HbA1c marker, Diabetic dyslipidemia, Type 2 diabetes mellitus	en_US
dc.title	HbA1c as a Marker of Diabetic Dyslipidemia in Type 2 Diabetic Patients: A Cross Sectional Study.	en_US
dc.type	Article	en_US